Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Benign Breast Disease/DCIS Team Project
Team Project

Benign Breast Disease/DCIS Team Project

331
A.   Paul Cairns (DNA Methylation Sensitivity in IBC) MAL          RASSF IA       CTGF          HIN1          APC          RAR          GSTP1       IGFBP3       GOS2          B.   Andrew Godwin (Protein Biomarker) C.   Indra Poola (Protein Biomarker) MMP-1 CEA CAM6 HYAL-1 D.   Nicole Urban CAV-1 (Caveolin 1) FN-1 (fibronectin) COL1A1 TIMP4 SPP1 (osteopontin) S100A7 (Psoriasin) MMP10 MMP12
Proteomics
Other, Specify
Breast and Gynecologic Cancers Research

To identify women diagnosed with atypical ductal hyperplasia (ADH) who are at increased risk of developing invasive breast cancer (IBC) and who might benefit from risk reduction with the use of chemoprevention agents such as Tamoxifen. (Note: A companion protocol will study women with DCIS and their risk for invasive breast cancer.)

Biomarkers expressed in benign breast disease tissue of women who progresse to invasive breast cancer are quantitatively and/or qualitatively different from those expressed in tissue of matched women who do not progress to invasive breast cancer. A nested case-control design will be used to determine if available proteomic and methylation biomarkers predict risk for future invasive cancer (IBC). Women with ADH who are disease-free will be matched 2:1 to women with ADH who progress to IBC.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html